Studies have shown that taking Venetoclax before CAR-T-cell therapy can upregulate the expression of CD19 and proapoptotic proteins in B-CLL cells, resulting in increased cytotoxicity and the persistence of CD19 CAR-T cells [72]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.